Ivermectin Moves Towards Mainstream

Ivermectin Moves Towards Mainstream

Recently, the National Institutes of Health (NIH) got around to formally addressing ivermectin in their COVID-19 Treatment Guidelines. Although their only recommendation is for use in clinical trials, that’s a start. TrialSite has been working tirelessly to chronicle and accumulate data centering on the off-label use, case series, observational and randomized clinical trial information possibly pointing to the future acceptance of this cheap and available drug as but one possible contributing way to help fight COVID-19. TrialSite has reported that in at least three randomized clinical trials (Egypt, Bangladesh, and Iraq), the use of the drug targeting early-stage COVID-19 patients leads to positive results; in addition to several observational and hospital approved case series efforts, TrialSite applauds the nation’s research institution for at least taking the time to acknowledge and review the recent Broward County study led by Dr. Jean Jacques Rajter. The apparent fact that this generic drug, which costs about $7 per pill in the US, may be useful as a treatment to alleviate symptoms of COVID-19 is given traction in the mainstream media in the United States as the Miami Herald recently embraced the topic showcasing the Broward County physician and his ICON study results. They also emphasized several doctors in Florida who are prescribing the drug, including Key West-based Dr. Bruce Boros, who reports that he is using the drug successfully to help COVID-19 patients in South Florida.   

It all Starts in Australia

TrialSite commends the Miami Herald and journalist David Goodhue for making a good faith attempt to introduce this controversial topic to the mainstream in a relatively fair and balanced way. The scientific roots of the interest in ivermectin go back to the spring, during the onset of the pandemic when researchers in Australia were working furiously to explore possible ways to fight off this novel coronavirus. The result of a collaborative study led by Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute)—a joint venture of the University of Melbourne and Royal Melbourne Hospital—revealed that ivermectin kills SARS-CoV-2. 

Back in early April, TrialSite first reported on these findings. The response was overwhelming—in aggregate, some of the articles received well over a hundred thousand visits. The Monash-led study revealed that this anti-parasitic drug widely available worldwide could destroy the SARS-CoV-2 virus within 48 hours in a cell culture. The university showed the importance of, and urgency for, clinical research funding to support an effort to find effective dosages that are safe for humans. Ivermectin, FDA approved, is widely used in the tropics today to combat parasite-born disease. The Monash University-led collaborative study was published in Antiviral Research, a peer-reviewed medical journal published by Elsevier

Use of Ivermectin Targeting COVID-19 Expands: But Why?

TrialSite chronicled how the use of ivermectin spread around the world right after the Monash findings, especially in low and middle-income countries (LMICs), but also in the United States and France. From the Andes to India, from the Amazon to Bangladesh, the use of ivermectin spread rapidly. But why? Was it simply based on the early-stage research of Monash, or was there additional evidence? No one knew with any certainty. In a quest to learn more, TrialSite monitored the press, medical reports, national regulatory and research agencies worldwide and conducted a series of interviews. We brought in Carlos Chaccour, one of the world’s top ivermectin specialists, heavily involved with significant research. TrialSite showcased the work Bangladesh Medical College’s Dr. Tarek Alam, who observed considerable success with treating COVID-19 with ivermectin—reporting a 98% success rate in Dhaka. An interview with Dr. Jose Natalio Redondo, president of Dominican Republic’s leading private hospital network, Grupo Rescue, revealed a near 100% success rate; Dr. Redondo declared at the time of the interview that the health system had documented clear success in treating 1,300 early-stage COVID-19 patients with ivermectin. 

TrialSite researchers became more intrigued and tracked and monitored ivermectin research around the world, including the production of an original documentary “How Peru Uses Ivermectin” to help get to the bottom of why the use of this drug was accelerating worldwide. Based on a substantial amount of research, it becomes apparent that at least in many LMICs and even in some cases in the US, the urgency of the pandemic led to a grass roots, physician-driven push to explore the use of the drug targeting COVID-19, at least in the early stages of the disease. Medical professionals needed to act, as patients were dying and with a lack of any established, approved, and effective medication, the Monash study incited a wave of “real world” experimentation during the pandemic. 

All involved physicians, from Peru to Bangladesh to India and Mexico to the US, agree that we need randomized controlled trials. That is the net takeaway from the TrialSite Peru documentary as well.

From LMICs to Key Largo

The only difference between the position of the US FDA and NIH on the one hand, and the community-based physicians around the world on the other, are the practicalities on the ground—in a pandemic situation, there often isn’t the time, the money, or the resources in many parts of the world to conduct research and then clinical practice in a serial fashion (e.g., first lengthy randomized trials and then treatment). Rather many felt compelled based on health urgency to work in parallel. That is, they knew the safety profile of ivermectin and hence prescribed off-label, carefully monitoring, documenting, and continuing assessing results. Thus far, the results have been overwhelmingly positive, but this is not evidence for purposes of a listing under the NIH COVID-19 Treatment Guidelines. Yet Dr. Bruce Boros operates a clinic in Key Largo, Florida, and The Miami Herald reports he has become a proponent for using the drug to treat COVID-19 patients—much like Dr. Rajter to the north in the Fort Lauderdale area. The cardiologist owns and operates Advanced Urgent Care clinics on the island chain. A pragmatic physician and businessman, Boros was an early advocate warning about the danger of COVID-19—he was apparently pro-social distancing and other measures such as stopping tourism early on in the pandemic’s trajectory.

Ivermectin Part of the Broward County Drug Portfolio

The Miami Herald’s Goodhue introduces one Dave Lacknauth, executive director of pharmacy services and system integration at Broward Health, a four-hospital network. Again, it was this health system that approved the use of ivermectin for the Dr. Jean Jacques Rajter/ICON study. The Miami Herald uncovered that the South Florida health system maintains a “portfolio” of drugs used by its doctors to treat patients infected with SARS-CoV-2, the virus behind COVID-19. These include not only ivermectin, but also the controversial drugs hydroxychloroquine and remdesivir. None of these therapies, including those approved for emergency use authorization (e.g., remdesivir or convalescent plasma), are “cures.” As mentioned previously, the Miami Herald story reminds the reader that absolutely no clinical evidence exists for the effective use of the drug. Rather health systems and providers in various parts of the world are doing their part to do their best to save lives with imperfect science.

TrialSite notes that the US currently spends billions of dollars on vaccines and high-priced therapies that are also scientifically unproven. NIH should adapt to include some real-world studies; there are over 30 clinical trials of ivermectin ongoing in multiple countries, including the US. A few of these trials are completed and evidence positive results. And of course, there may be more money to be made in new therapies backed by the massive government and private funds, versus the humble ivermectin. Given the severity of the pandemic worldwide, why wouldn’t governments around the world be more curious about prospective low-cost, economical options to inhibit this insidious pathogen?

Call to Action: Read the Miami Herald story by David Goodhue. Although TrialSite has certain critiques, the fact of the matter is that the publication and the journalist showed the courage to raise the topic, and for that, they are commended.


  1. The best treatment plan for mild-to-moderately ill COVID19 patients is : – Ivermectin 12mg daily for 3 to 6 days + Bromhexine 8mg thrice daily for 10 days + Zinc + Vitamin D + Vitamin C + Cefuroxime 500mg twice daily after food for 10 days. If blood oxygen saturation tends to fall, inhaled corticosteroid (ICS) should be initiated. I follow this outdoor treatment plan in my practice; and none of my patients became too ill to get intensive treatment indoor.

    Arun Kumar Laha 03 09 2020

    1. Dr. Laha, thank you for sharing your expertise! This level of information and guidance is very helpful for physicians worldwide. You mentioned the addition of ICS at the onset of hypoxia. Have you considered early administration (symptom onset) of Ciclesonide ICS? There is good data on Ciclesonides strong antiviral activity against SARS-CoV-2 and it has very minimal immunosuppresion effects. Here is a link to a review of data on it and other ICS therapeutics: https://www.cebm.net/covid-19/inhaled-corticosteroids-a-rapid-review-of-the-evidence-for-treatment-or-prevention-of-covid-19/

    2. But even the antiparasitic dose is 3-3.5 mg per 10 kg of body weight. With this dosage, the symptoms disappear in a maximum of two days. It was checked in five cases, the side effect is minimal (in one case, the violation of microflora).

  2. Thank you for your brave leadership. Professor Thomas Borody , in Australia, is using a protocol that includes Ivermictin. He provides the protocol to GP’s upon request. Independent of Professor Borody, a Facebook group, The People’s Medicine was created to focus on the Borody Plan. A number of Doctors are members of the Facebook group Ivermectin MD. Search Facebook groups for several other groups that focus on ivermectin. Facebook is suppressing information about Ivermictin. Many governments are discouraging or even forbidding the use of Ivermictin vs Covid 19.

    1. John, I’ve searched extensively for Dr. Borody’s specific dosing but haven’t uncovered it. Typically, IVM is dosed at 200mcg/kg single dose. Some protocols add additional dosing at different intervals. There is a trial testing higher doses at 600mcg/kg against another arm at 1200mcg/kg (NCT04438850). Currently, IVM is approved in the US at up to 400mcg/kg for some conditions. There was a study that showed even 2000mcg/kg did not cause any serious adverse effects.

      With a half life of 18hrs an emerging dosing strategy is multiple doses (2-3) of around 200mcg/kg every other day.

      1. Hi Paul,

        animal studies are actually quite clear in indicating not only good partitioning to lung, but long-term stability. The peer-reviewed modelling publication from Liverpool Uni. based on this indicates that standard dosing (200 mcg/kg) should be therapeutic in humans.


        See 48. Arshad, U.; Pertinez, H.; Box, H.; Tatham, L.; Rajoli, R.K.R.; Curley, P.; Neary, M.; Sharp, J.; Liptrott, N.J.; Valentijn, A.; David, C.; Rannard, S.P.; O’Neill, P.M.; Aljayyoussi, G.; Pennington, S.H.; Ward, S.A.; Hill, A.; Back, D.J.; Khoo, S.H.; Bray, P.G.; Biagini, G.A.; Owen, A. Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived From Their Established Human Pharmacokinetics. Clin Pharmacol Ther. 2020, doi: 10.1002/cpt.1909.

    2. my experience

      since march i was using hydroxycholoquine 200mg weekly with my 75 hospital staff since march and added ivermectin 600mg monthly from june 2020 .my two medicine shop staff didnot took it.both suffered from covid and has to be admitted in covid icu at patna.one recovered in 2weeks in icu with bipap for one weeks in age of 44yrs.another 34 yrs guy has to be incovid icu for 34days from bipap7days ventilator 12days with tracheostomy tube 20days.
      husband of my 2 staff nurse became covid positive but both nurses remained negative throughout in a busy hospital of 55bed with13icu 8 hdu 3ot etc.

      so my recommendation for hospital staff is 200mg hydroxychloroquine once a week and 600mg ivermectin once a month for prophylaxis

      dr sanjay kumar ishwar hospital begusarai bihar

  3. Is anyone doing a controlled study using Ivermectin alone? All the studies I’ve seen include one or more other substances, making it difficult if not impossible to determine the efficacy of Ivermectin itself.

    1. We are doing a trial of ivermectin alone in Lagos Nigeria. We are doing ivermectin 12mg twice weekly for two weeks in one arm, 6mg twice weekly in another arm and Lopinavir/aRitinavir in the third arm. We have dosed about 40 patients so far. The hard endpoint is viral loads measured five times serially per patient. So far our results suggest ivermectin 12mg arm clears the virus by day 2-3 in 25% of cases and by day 5 in 50%. We are still setting up the website where we will post more detailed results.

      1. Prof Babaloala, many thanks for sharing your early results with Ivermectin. Hoping the final results show the remaining PCR+ patients cleared at the final endpoint. Regardless of the final results your efforts are greatly appreciated for adding to the clinical data!

  4. As someone who just spent the past several days trying to keep her dog alive after an accidental ivermectin (heart worm preventative) overdose, I find this article mildly terrifying. Not that doctors are exploring this as a treatment, but that it is so easily available for such a cheap price when sold for farm animal use. People will see this and attempt to medicate themselves, and some will think more is better.

    1. Some dog breeds are hypersensitive to Iverectin, such as collies and shelties or similar breeds. In humans, if such hypersensitivity occurs, it is extremely rare. Ivermectin has an incredibly safe use profile. Hundreds of millions take ivermectin every year.
      There is evidence that accidental use of ivermectin in pregnant women did not cause any side effects in women and their children. I read this on the World Health Organisation website.
      Of course, treating yourself without the advice of doctors is not very good.. But it’s сукефштдн better to heal yourself than to die in the hands of a “highly professional” doctor who is unwilling to prescribe a drug that is obviously life saving because “no randomized trials have been done”.
      I personally find it deeply unethical to be able to save a patient’s life, but not to do so in accordance with outdated instructions from health officials.

  5. It is surprising that even after 7 to 8 mnths of pandemic we donot have any evidence based study protocol despite enormous volume of data of patidnts.98 percent of patients r improving with any kind of combination of drugs but rest those 2% few of these things wrk unless intervened with steroids etc early on.

    1. Ivermectin works 100 %.I will suggest also Doxycycline for 10 days (the only antibiotic that works on SARS) and TMZ for 10 days ( works on SARS and HIV) Hope my suggestions will be taken into consideration.
      Dr Cornel Dehelean MD

    2. As current research is to attract funds and grants, after 8 months also no evidence based medicine.
      Ivermectin, long ago FDA approved drug for parasitic infections. This type of articles (publications and news) do more harm than good in developing countries, due to overdose and side effects. So far, ivermectin killed every virus in the world, in vitro. Claps for the panacea.

  6. My comment is outrage and disgust at the obvious collusion between the majority of the governments,the majority of the media,and the drug mafia.The Miami Herald certainly deserves praise and commendation for their courage sticking on this story.Hopefu)ly they’ll get an “Excellence in journalism award” for it.But where is the rest of them?

    1. I concur with your opinion and as a Cardiovascular specialist since 1981 I have seen a great many pharmacological and device implementations that have been amazing to be part of. I am filled with consternation that in the USA that Ivermectin with zinc, vit D, vit C, famotidine, baby aspirin, and Tylenol or ibuprofen has been totally OMITTED as an inexpensive and effective treatment for CV 19. It is blatantly obvious to any Frontline physician that even if was only 50% effective the cost benefit and risk benefit ratios scream out to utilize this combination of medications. I do use azithromycin or doxycycline for 5 days as well.
      It saddens me to be at this point in Medicine where profit is the major driver of health care. Big Pharma and medical device companies own Washington. Everything is now politicized.
      Bruce L Boros MD FACC
      Owner of 3 Advanced Urgent Care
      Facilities in Monroe County Florida

      We are testing with pcr, starting the protocol and if pcr is negative I continue everything except the antibiotic for 1 week total. I give 0.4mg per kilogram body weight over 3-4 hours if the dose is above 30mg. I call the patient later to check and see how they feel and if they need to take the remaining dose and they are stable I have them take the rest of the dose. THE PATIENTS REALLY APPRECIATE THE FOLLOW UP CALL. Old time caring! I then call them daily for a quick check up on their status. 21 patients took full dosage of Ivermectin without any significant side effects. IMO stopping the viral replication as early as possible may diminish the Post Covid Syndrome. Just a feeling

      1. Thanks for your thoughts Dr. Bruce. Im myself a frontline physician and i agree 200% with your opinion. It saddens me too that many physicians are screaming “X has no evidence”.
        do we need to wait 4-5 months to initiate a treatment when we receive 5-10 moderately-critically ill persons each day? Theres tons of literature about medicaments we use everyday that can suggest they are useful somehow in CV19 without doing harm 98% of the time. And im sure these ones are the ones that have zero contact with covid 19 patients in the Urgency department, since doing teleconsult is a whole different thing.

  7. Hi David, there are actually 54 clinical trials for ivermectin worldwide. I can provide the list if that is helpful to you.

      1. Best might be a pdf (this is a table):

        Table 2. Summary of Current Clinical Trials using Ivermectin for SARS-CoV-2.
        Title, URL Status1 N2 Interventions3 Start Locations
        1 Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19; https://ClinicalTrials.gov/show/ NCT04381884 R 45 Ivermectin 0.6 mg/kg QD plus SC vs. SC 18.5.20 CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina
        2 Ivermectin and Nitazoxanide Combination Therapy for COVID-19; https://ClinicalTrials.gov/show/ NCT04360356 NY 100 Ivermectin 0.2 mg/kg once plus NZX 500 mg BID for 6 days vs. SC 20.5.20 Tanta University, Egypt
        3 Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19; https://ClinicalTrials.gov/show/ NCT04429711 R 100 Ivermectin 12-15 mg/day for 3 days vs. Placebo 12.5.20 Sheba Medical Center, Ramat-Gan, Israel
        4 Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection; https://ClinicalTrials.gov/show/ NCT04391127 R 200 Ivermectin 12 mg ( 80 kg) once vs. HCQ 400 mg BID for 1 day then 200 mg BID for 4 days vs. Placebo 4.5.20 Jose Manuel Arreola Guerra, Aguascalientes, Mexico
        5 Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19. https://ClinicalTrials.gov/show/ NCT04405843 NY 400 Ivermectin 0.3 mg/kg daily for 5 days vs. Placebo 20.6.20 Colombia
        6 Ivermectin In Treatment of COVID 19 Patients. https://ClinicalTrials.gov/show/ NCT04425707 R 100 Ivermectin (dose unlisted) vs. SC vs. Ivermectin (dose unlisted) plus SC 9.6.20 Isolation and referral hospitals for COVID 19 patients, Cairo, Egypt
        7 Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection; https://ClinicalTrials.gov/ show/ NCT04407130
        E 72 Ivermectin 0.2 mg/kg once plus 200 mg DOC day 1 followed by 100 mg DOC BID for 4 days vs. Ivermectin 0.2 mg/kg QD for 5 days vs. Placebo 16.6.20 Icddr,B, Dhaka, Bangladesh
        8 Efficacy of Ivermectin as Add on Therapy in COVID19 Patients.
        https://ClinicalTrials.gov/show/ NCT04343092 C 100 Ivermectin 0.2 mg/kg once weekly plus HCQ 400 mg QD plus ATM 500 mg QD vs. HCQ 400 mg QD plus ATM 500 mg QD 18.4.20 General Directorate of Medical City, Bagdad, Baghdad, Iraq
        9 COVidIVERmectin: Ivermectin for Treatment of Covid-19 (COVER).
        https://ClinicalTrials.gov/show/ NCT04438850 NY 102 Ivermectin 0.6 mg/kg QD for 5 days vs. Ivermectin 1.2 mg/kg QD for 5 days vs. Placebo 20.6.20 Negrar, Verona, Italy; Bologna, Italy; Milan, Italy; Rovereto, Italy; Turin, Italy; Barcelona, Spain; Madrid, Spain
        10 Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms (SILVERBULLET).
        https://ClinicalTrials.gov/show/ NCT04407507 NY 66 Ivermectin 12 mg/day for 3 days plus paracetamol 500 mg QID for 14 days vs. Placebo plus paracetamol 500 mg QID for 14 days 20.6.20 Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V., Mexico
        11 Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial (SAINT).
        https://ClinicalTrials.gov/show/ NCT04390022 R 24 Ivermectin 0.4 mg/kg once vs. Placebo 14.5.20 Clinica Universidad de Navarra, Pamplona, Navarra, Spain
        12 A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh.
        https://ClinicalTrials.gov/show/ NCT04434144 C 116 Ivermectin 0.2 mg/kg once plus DOC 100 mg BID for 10 days vs. HCQ 400 mg day 1 then 200 mg BID for 9 days plus ATM 500 mg/day for 5 days 2.5.20 Chakoria Upazilla Health Complex, Cox’s Bazar, Bangladesh
        13 Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection (IDRA-COVID19).
        https://ClinicalTrials.gov/show/ NCT04435587 NY 80 Ivermectin 0,6 mg/kg daily for 3 days vs. HCQ 400 mg BID Day 1 then 200 mg BID for 4 days plus Darunavir/ritonavir (400 mg/100 mg) BID for 5 days 20.7.20 Siriraj Hospital, Bangkok Noi, Bangkok, Thailand
        14 IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19. https://ClinicalTrials.gov/show/ NCT04425863 A 100 Ivermectin 5 mg/ml oral to be repeated 1 week later (dose unlisted) 1.5.20 Hospital Eurnekian, Buenos Aires, Argentina
        15 A Preventive Treatment for Migrant Workers at High-risk of Covid-19.
        https://ClinicalTrials.gov/show/ NCT04446104 R 5000 Ivermectin 12 mg once vs. HCQ 400 mg day 1 then 200 mg/day for 42 days vs. Zinc 80 mg/day plus vitamin C 500 mg/day for 42 days vs. Povidone-iodine throat spray TID for 42 days vs. Vitamin C 500 mg/day for 42 days 13.5.20 Tuas South Dormitory, Singapore, Singapore
        16 New Antiviral Drugs for Treatment of COVID-19.
        ttps://ClinicalTrials.gov/show/ NCT04392427 NY 100 Ivermectin (dose unlisted) plus NZX (dose unlisted) plus ribavirin 200 mg or 400 mg vs. Control (untreated) 20.5.20 Mansoura University, Mansoura, Select A State Or Province, Egypt
        17 Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection (TITAN).
        https://ClinicalTrials.gov/show/ NCT04447235 NY 176 Ivermectin 12 mg once plus losartan 50 mg/day for 15 days vs. Placebo 20.7.20 Instituto do Cancer do Estado de São Paulo, Brazil
        18 Ivermectin in Treatment of COVID-19.
        https://ClinicalTrials.gov/show/ NCT04445311 R 100 Ivermectin daily (dose unlisted) for 3 days plus SC vs. SC 31.5.20 Waheed Shouman, Zagazig, Sharkia, Egypt
        19 Efficacy of Ivermectin in COVID-19.
        https://ClinicalTrials.gov/show/ NCT04392713 R 100 Ivermectin 12 mg once plus SC vs. SC 15.4.20 Combined Military Hospital Lahore, Lahore, Punjab, Pakistan
        20 Ivermectin and Doxycycine in COVID-19 Treatment.
        https://ClinicalTrials.gov/show/NCT04403555 NY 40 Ivermectin (dose unlisted) plus DOC (dose unlisted) vs. CQ (dose unlisted) 1.6.20 Sherief Abd-Elsalam, Tanta, Egypt
        21 The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment.
        https://ClinicalTrials.gov/show/ NCT04351347 R 300 Ivermectin (dose unlisted) vs. Ivermectin (dose unlisted) plus NZX (dose unlisted) vs. Ivermectin (dose unlisted) plus CQ (dose unlisted) 16.6.20 Tanta University, Tanta, Egypt
        22 Prophylactic Ivermectin in COVID-19 Contacts.
        https://ClinicalTrials.gov/show/ NCT04422561 C4 304 Ivermectin 15 mg (40-60 kg), 18 mg (60-80 kg) or 24 mg (> 80 kg) per day, 2 doses 72 h apart vs. Control (untreated) 31.5.20 Zagazig University, Zagazig, Sharkia, Egypt
        23 Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study.
        https://ClinicalTrials.gov/show/ NCT04373824 R 50 Ivermectin 0.2 mg/kg daily for 2 days plus SC vs. SC 25.4.20 Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India
        24 A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19 (IFORS)
        https://ClinicalTrials.gov/show/ NCT04431466 NY 64 Ivermectin 0.1 mg/kg once vs. Ivermectin 0.1 mg/kg day 1 and repeated after 72 h vs. Ivermectin 0.2 m/kg once vs. Ivermectin 0.2 mg/kg day 1 and repeated after 72 h vs. SC 1.7.20 Hospital Univeristário da Universidade Federal de São Carlos (HU-UFSCar), São Carlos, São Paulo, Brazil
        25 Novel Agents for Treatment of High-risk COVID-19 Positive Patients
        https://ClinicalTrials.gov/show/ NCT04374019 R 240 Ivermectin 12 mg (75 kg) daily for 2 days vs. HCQ 600 mg/day for 14 days plus ATM 500 mg day 1 then 250 mg/day for 4 days vs. Camostat Mesilate 200 mg TID for 14 days vs. Artemesia annua 50 mg TID for 14 days 1.5.20 University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
        26 Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19 (IvAzCol)
        https://ClinicalTrials.gov/show/ NCT04399746 R 30 Ivermectin 6 mg/day on days 0, 1, 7 and 8 plus ATM 500 mg/day 4 days plus Cholecalciferol 400 IU BID for 30 days vs. Control (untreated) 15.3.20 Outpatient treatment, Mexico City, Mexico
        27 USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 (IVERCAR)
        https://ClinicalTrials.gov/show/ NCT04425850 A5 1195 Ivermectin (topical for oral mucosae) plus iota carrageenan (topical for oral mucosae) 5 times per day plus PPE vs. PPE only 1.6.20 Hospital Eurnekian, Buenos Aires, Argentina
        28 Novel Regimens in COVID-19 Treatment
        https://ClinicalTrials.gov/show/ NCT04382846 NY 80 Ivermectin plus CQ (dose unlisted) vs. Ivermectin plus NZX (dose unlisted) vs. Ivermectin plus NZX plus ATM (dose unlisted) vs. NZX and ATM (dose unlisted) 8.5.20 Tanta University, Egypt
        29 Anti-Androgen Treatment for COVID-19
        https://ClinicalTrials.gov/show/ NCT04446429 NY 254 Ivermectin 0.2 mg/kg QD plus ATM 500 mg QD vs. Ivermectin 0.2 mg/kg QD plus ATM 500 mg QD plus Dutasteride 0.5 mg QD 26.6.20 Corpometria Institute, Brasilia, Brazil
        30 A Real-life Experience on Treatment of Patients With COVID 19 https://ClinicalTrials.gov/show/ NCT04345419

        R 120 Ivermectin (dose unlisted) vs. CQ (dose unlisted) vs. Favipiravir (dose unlisted) vs. NZX (dose unlisted) vs. Niclosamide (dose unlisted) vs. other drugs (oseltamivir or combination of above, dose unlisted) 16.6.20 Tanta university hospital, Tanta, Egypt
        31 Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic (observational)
        https://ClinicalTrials.gov/show/ NCT04460547 NY 200 Completed interventional vs. completed observational studies on Ivermectin, Convalescent Plasma, HCQ, DAS181, or Interferon 1A 25.7.20 Qassim University, Saudi Arabia
        32 Trial of Combination Therapy to Treat COVID-19 Infection
        https://ClinicalTrials.gov/show/ NCT04482686 NY 300 Ivermectin (dose unlisted) day 1 and 4 plus DOC (dose unlisted) for 10 days plus Zinc for 10 days plus Vitamin D3 for 10 days plus Vitamin C for 10 days vs. Placebo 22.7.20 ProgenaBiome, California, USA
        33 Randomised clinical trial of ivermectin for treatment and prophylaxis of COVID-19 https://www.clinicaltrialsregister.eu/ ctr-search/trial/2020-001994-66/ES O 266 Ivermectin (dose unlisted) vs. Placebo 8.5.20 Fundació Assistencial Mútua Terrassa, Spain

        34 Multicenter, randomized, double-blind, placebo-controlled study investigating efficacy, safety and tolerability of ivermectin HUVE-19 in patients with proven SARS-CoV-2 infection (COVID-19) and manifested clinical symptoms. https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002091-12/BG
        O 120 Ivermectin 0.4 mg/kg plus SC vs. Placebo plus SC 5.5.20 Bulgaria (9 sites)
        35 Efficacy of hydroxychloroquine, ciclesonide and ivermectin in treatment of moderate covid-19 illness: an open-label randomised controlled study (EHYCIVER-COVID)
        http://ctri.nic.in/Clinicaltrials CTRI/2020/04/024948 NY 120 Ivermectin 12 mg/day for 7 days vs. Ciclesonide 0.2 mg/kg BID for 7 days vs. HCQ 400 mg BID Day 1 then 200 mg BID for 6 days vs. SC 15.5.20 New Delhi, India
        36 A Phase IIB open label randomized controlled trial to evaluate the efficacy and safety of Ivermectin in reducing viral loads in patients with hematological disorders who are admitted with COVID 19 infection
        http://ctri.nic.in/Clinicaltrials CTRI/2020/04/025068 NY 50 Ivermectin 3 mg (15-24 kg) or 6 mg (25-35 kg) or 9 mg (36-50 kg) or 12 mg (51-65 kg) or 15 mg (66-79 kg) or 0.2 mg/kg (80 kg) once vs. SC 27.5.20 Christian Medical College Vellore, TAMIL NADU, India
        37 Interventional study to assess the efficacy of Ivermectin with standard of care treatment versus standard of care in patients of COVID-19 at R D Gardi Medical College, Ujjain, India
        http://ctri.nic.in/Clinicaltrials CTRI/2020/04/025224 NY 50 Ivermectin 12 mg/day for 2 days plus SC vs. SC 24.5.20 R D Gardi Medical College, Ujjain, Madhya Pradesh, India
        38 Study to assess the efficacy of Ivermectin as prophylaxis of COVID 19 among health care workers and COVID 19 contacts in Ujjain, India; http://ctri.nic.in/Clinicaltrials CTRI/2020/04/025333 NY 2000 Ivermectin 12 mg/day (adult) or 6 mg/day (children) for 2 days vs. Control 27.5.20 R D Gardi Medical College, Ujjain, Madhya Pradesh, India
        39 Randomised Controlled Trial of Ivermectin in hospitalised patients with COVID19 (RIVET-COV).
        http://ctri.nic.in/Clinicaltrials CTRI/2020/04/026001 NY 60 Ivermectin single dosing of 0.2 mg/kg vs. Ivermectin 0.4 mg/kg vs. Ivermectin 0.8 mg/kg vs. Ivermectin 1.6 mg/kg vs. Ivermectin 2 mg/kg vs. SC 25.6.20 New Delhi, India
        40 A Prospective, randomized, single centred, open labelled, two arm, placebo-controlled trial to evaluate efficacy and safety of Ivermectin drug in patients infected with SARS-CoV-2 virus; http://ctri.nic.in/Clinicaltrials CTRI/2020/04/025960 NY 100 Ivermectin 12 mg/day for 3 days vs. SC 18.6.20 Symbiosis University Hospital and Research Centre, Maharashtra, India
        41 A Clinical Trial to Study the Efficacy of “Ivermectin” in the prevention of Covid-19. A Single Arm Study. http://ctri.nic.in/Clinicaltrials CTRI/2020/04/026232 NY 50 Ivermectin 0.2 mg/kg once 10.7.20 DVFM, Andhra Pradesh, India

        42 Ivermectin Nasal Spray for COVID19 Patients. https://ClinicalTrials.gov/show/
        NCT04510233 NY 60 Ivermectin nasal spray (1 ml) in each nostril BID vs. Ivermectin oral (6 mg) TID vs. SC 10.8.20 Tanta University, Tanta, Egypt
        43 Outpatient use of ivermectin in COVID-19. https://ClinicalTrials.gov/show/ NCT04530474 NY 200 Ivermectin 0.15-0.2 mg/kg (max 12 mg) once vs. Placebo 26.8.20 Temple University Hospital, Philadelphia, USA
        44 Ivermectin to prevent hospitilizations in COIVD-19.
        https://ClinicalTrials.gov/show/ NCT04529525 R 500 Ivermectin 12 mg (48-80 kg) or 18 mg (80-110 kg) or 24 mg (>100 kg) at inclusion and again at 24h vs. Placebo 21.8.20 Ministry of Public Health, Province of Corrientes, Argentina
        45 Clinical trial of ivermectin plus doxycycline for the treatment of confirmed Covid-19 infection. https://ClinicalTrials.gov/show/ NCT04523831 R 400 Ivermectin 6 mg and doxycycline 100 mg BID for 5 days vs. Placebo 19.8.20 Dhaka Medical College, Dhaka Bangladesh
        46 Pilot study to evaluate the potential of ivermectin to reduce COVID-19 transmission. https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001474-29/ES O 24 Ivermectin (dose unlisted) vs. Placebo 8.5.20 Clinica Universidad de Navarra, Pamplona, Spain
        47 Dose-Finding study of Ivermectin treatment on patients infected with Covid-19:A clinical trial. https://en.irct.ir/trial/47012 A 125 Ivermectin 0.2 mg/kg single dose plus SC vs. Ivermectin 0.2 mg/kg day 1, 2, 5 plus SC vs Placebo plus SC vs. Ivermectin 0.4 mg/kg day 1 and 0.2 mg/kg day 2, 5 vs. SC 4.5.20 Qazvin University of Medical Sciences, Qazvin, Iran
        48 In vivo use of ivermectin (IVR) for treatment for corona virus infected patients: a randomized controlled trial. http://www.chictr.org.cn/showprojen.aspx?proj=54707 NY 60 Ivermectin single dose 0.2 mg/kg vs. Placebo 10.6.20 Rayak Hospital, Riyaq, Lebanon
        49 A randomized clinical trial study, comparison of the therapeutic effects of Ivermectin, Kaletra and Chloroquine with Kaletra and Chloroquine in the treatment of patients with coronavirus 2019 (COVID-19). http://en.irct.ir/trial/48444 A 60 Ivermectin 0.15-0.2 mg/kg single dose day 1 plus HCQ 200 mg day 1 plus Lopinavir/Ritonavir 400/100 mg days 2-6 vs. HCQ 200 mg day 1 plus Lopinavir/Ritonavir 400/100 mg days 2-6 30.5.20 Ahvaz Razi Hospital, Ahvaz, Iran
        50 A double-blind clinical trial to repurpose and assess the efficacy and safety of ivermectin in COVID-19. http://isrctn.com/ISRCTN40302986 R 45 Ivermectin 6 mg every 3.5 days for 2 weeks vs. Ivermectin 12 mg every 3.5 days for 2 weeks vs. Placebo 23.4.20 Lagos University Teaching Hospital, Lagos, Nigeria
        51 Effectiveness of Ivermectin in the Treatment of Coronavirus Infection in Patients admitted to Educational Hospitals of Mazandaran in 2020. https://en.irct.ir/trial/49174 R 60 Ivermectin 0.2 mg/kg once plus SC vs. SC 21.5.20 Bouali Hospital, Sari, Iran
        52 Subcutaneous Ivermectin in Combination With and Without Oral Zinc and Nigella Sativa: a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients. https://clinicaltrials.gov/ct2/show/study/NCT04472585 R 40 Ivermectin 0.2 mg/kg subcutaneous injection every 2 days plus SC vs. Ivermectin 0.2 mg/kg subcutaneous injection every 2 days plus 80 mg/kg Nigella Sativa oral QD plus SC vs. Ivermectin 0.2 mg/kg subcutaneous injection every 2 days plus 20 mg Zinc Sulfate oral TID plus SC vs. Placebo plus SC 14.7.20 Shaikh Zayed Hospital, Lahore, Pakistan
        53 Pragmatic study “CORIVER”: Ivermectin as antiviral treatment for patients infected by SARS-COV2 (COVID-19). https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001971-33/ES O 45 Ivermectin 0.2-0.4 mg/kg (regime unlisted) vs. HCQ 400 mg vs ATM 500 mg vs. Placebo 22.7.20 Hospital Universitario Virgen de las Nieves, Granada, Spain
        54 Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel at All Levels of Care, During the 2020 Pandemic: A Randomized Clinical Controled Trial. https://clinicaltrials.gov/ct2/show/record/NCT04527211
        NY 550 Ivermectin 0.2 mg/kg weekly for 7 weeks vs. Placebo
        7.9.20 Pontificia Universidad Javeriana, Valle Del Cauca, Colombia

        1R, Recruiting, NY, Not yet recruiting, A, Active not recruiting, C, Completed, E, Enrolling by invitation, O, ongoing
        2Number of patients
        3SC, standard care, QD, once per day, BID, twice daily, QID, 4 times daily, TID, 3 times daily, PPE, personal protective equipment, vs. versus, HCQ, hydroxychloroquine (US. Food and Drug Administration approval was rescinded for COVID-19) [44,45]; DOC, doxycycline; CQ, chloroquine, ATM, Azithromycin, NZX, Nanozoxide
        4Raw data for asymptomatic family close contacts of confirmed COVID patients show that 2 doses of ivermectin 72 h apart resulted in only 7.4% of 203 subjects reporting symptoms of SARS-CoV-2 infection, in contrast to control untreated subjects, of whom 58.4% reported symptoms; evidence of prophylaxis.
        5Preliminary results for 1195 subjects are consistent with prophylaxis.

  8. A special thank you and commendation are due to TrialSiteNews for trying to keep us abreast of national and doctor-team responses to COVID-19 around the world. It should be clear to everyone by now that a huge block of the leadership of the part of humanity that lies outside of the 6% have decided that their needs do not allow them to wait for approvals of institutions within or dominated by the 6%.

    This network of institutions have their own politico-economic ecology and their needs, policies and procedures make sense in the context of that ecology (e.g., you must design the care system for late-disease-stage institutional responses to COVID-19 infections, and proposed treatments must be evaluated in terms of their utility in late-stage responses; because only them will the hungry institutions get fed properly). However, why would the rest of us in the world share those particular needs? Especially when it is quite obvious that brilliant COVID-19 related initiatives are breaking out all over the world, it is not to be expected that leaders outside of the 6% will assume that those institutional priorities apply to the whole world.

    Why does a One Size Fits All strategy for national public health and health-care-system deployment make sense in our world so heavily stamped with radical diversity in several domains? Did someone create an international health-advisory body on the assumption that this One Size Fits All business for countries makes sense?

    What proportion of TrialSiteNews 1,000,000 viewers come from the 6%? If it is disproportionately large, then the thrust and targets of your advocacy make sense 100%. In this case, may I suggest an international edition of TrialSiteNews? Here we could focus more strongly on the rest of the world (the 94%) and grant hero status to the leaders of the research and medical teams doing great work in a wide variety of countries.

  9. Thanks to all for the information. Here in the UK the official advice is “There is currently no specific treatment for coronavirus (COVID-19), but you can often ease the symptoms at home until you recover.” Ibufrofen or Paracetomol.
    I have obtained supplies of Melatonin, Doxycycline NAC, Quercetol Vit D and am trying to source Ivermectin. On the assumption I obtain the Ivermectin and get a positive test what combination of these should I take? Also available is Asthma inhaler Becotide.
    Thanks JW

    1. John, while this isn’t medical advice I’d be very cautious on using Becotide ICS too early (during the viral replication phase). IMO, a much better option for early administration is Ciclesonide ICS (aka: Alvesco). It’s shown potent antiviral activity against SARS-CoV-2 and it’s much less immunosuppresive than other ICS options i.e. budesonide. Here is a well organized review of the data from our friends from across the pond 😉